The same company that The Michael J. Fox Foundation has funded for a clinical trial of a Parkinsonís disease-modifying drug recently announced positive results from a study of its drug aiming to slow Alzheimerís progression.
Austrian-based biotech AFFiRiS last week held a press conference to release the results of a Phase II study of its compound AD04 in Alzheimerís patients. They reported that nearly half of patients (47 percent) treated with AD04 experienced effects consistent with disease modification. This beneficial effect was dose dependent and more effect in early-disease patients.
AFFiRiS is also testing a Parkinsonís-modifying treatment. MJFF funded the Phase I trial of AFFITOPEģ PD01, a vaccine approach to slowing the progression of PD. AFFiRiS will announce the results of that trial later this year.
Read more about the PD01 trial.